Obsidian Therapeutics, Inc.
- OBX · Nasdaq
- Pharmaceutical Preparations
- Cambridge, MA
- CIK 0002130606
Updated from SEC filings through
Top things to know
Next earningsFebruary 21, 2027Estimated from past filings
Latest 8-KResults of operations and financial conditionFiled November 12, 2026 Executives
-
Madan Jagasia Chief Executive Officer Form 4, August 5, 2026 - Julie B. Feder Chief Financial Officer Form 3, August 3, 2026
- Parameswaran Hari Chief Medical Officer Form 3, August 3, 2026
Obsidian Therapeutics, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Cambridge, MA. It trades as OBX on Nasdaq. Madan Jagasia is Chief Executive Officer.
Five-year financials
We have no annual financials for this company yet.
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Biotechnology Executive | Chief Executive Officer | Form 4, August 5, 2026 |
| Julie B. Feder CFO | Chief Financial Officer | Form 3, August 3, 2026 |
| Parameswaran Hari Chief Medical Officer , Obsidian Therapeutics | Chief Medical Officer | Form 3, August 3, 2026 |
What Obsidian Therapeutics, Inc. does
Obsidian Therapeutics is using its proprietary cytoDRiVE® platform to harness the power of proteins to engineer precision medicines.
Company website description, 10-K for the year ending November 7, 2026
Shares and governance
| Shares outstanding | 61.8 million (as of November 9, 2026) | 10-Q, November 12, 2026 |
|---|---|---|
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 12, 2026 |
Recent 8-K events
- 8-K filed 2026-11-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-03
- Item 1.01 Entry into a material definitive agreement
- Item 2.01 Completion of acquisition or disposition of assets
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 3.02 Unregistered sales of equity securities
- Item 3.03 Material modification to rights of security holders
- Item 4.01 Changes in registrant's certifying accountant
- Item 5.01 Changes in control of registrant
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Obsidian Therapeutics, Inc.
- What does Obsidian Therapeutics, Inc. do?
- In its own words, from Item 1 of its 10-K: "Obsidian Therapeutics is using its proprietary cytoDRiVE® platform to harness the power of proteins to engineer precision medicines."
- Who is the CEO of Obsidian Therapeutics, Inc.?
- Madan Jagasia, Chief Executive Officer, as named in a 4 filed August 5, 2026.
- Who is the CFO of Obsidian Therapeutics, Inc.?
- Julie B. Feder, Chief Financial Officer, as named in a 3 filed August 3, 2026.
- Where is Obsidian Therapeutics, Inc. headquartered?
- Cambridge, MA.
- What is Obsidian Therapeutics, Inc.'s stock ticker?
- OBX on Nasdaq.
- What industry is Obsidian Therapeutics, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Obsidian Therapeutics, Inc.'s website?
- obsidiantx.com. Investor relations: https://obsidiantx.com/investors-media/.
- When does Obsidian Therapeutics, Inc. report earnings next?
- February 21, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Obsidian Therapeutics, Inc. a public company?
- Yes. Obsidian Therapeutics, Inc. files with the SEC under CIK 0002130606 and trades as OBX.
- How many shares of Obsidian Therapeutics, Inc. are outstanding?
- 61.8 million shares as of November 9, 2026, from its 10-Q filed November 12, 2026.
- How many business segments does Obsidian Therapeutics, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 12, 2026.